AVEO Oncology, a subsidiary of LG Chem, announced that the first patient has been dosed in a Phase 1b/2 clinical study testing ficlatuzumab in combination with azacitidine and venetoclax for patients aged 60 and older with untreated acute myeloid leukemia. This study is conducted through a Master Clinical Trial Collaboration Agreement with Blood Cancer United, formerly known as the Leukemia & Lymphoma Society, which will sponsor the trial as part of its Beat AML Master Clinical Trial. The Beat AML program is a collaborative precision medicine trial that evaluates multiple therapies across different study arms simultaneously, aiming to accelerate treatment innovation for blood cancer patients.
Health Technology Insights: OrthAlign Expands Lantern Hip Platform for Posterior THA
The Phase 1b/2 study will assess the safety, pharmacokinetics, pharmacodynamics, and early efficacy of the combination therapy. Ficlatuzumab is a humanized IgG1 monoclonal antibody designed to target hepatocyte growth factor and block its interaction with the c-Met receptor. Previous early-phase studies combining ficlatuzumab with cytarabine in AML demonstrated a favorable safety profile and promising clinical activity, supporting further evaluation in patients who may not be candidates for intensive first-line therapy.
Health Technology Insights: Solventum Wins Diamond HIRC Badge for Top Supply Chain Strength
Michael P. Bailey, President and CEO of AVEO, said, “This milestone represents a meaningful step forward for AVEO and Blood Cancer United in our shared mission to improve outcomes for patients through innovative research. We are proud to advance this clinical trial and to continue expanding our pipeline of novel therapies for high unmet medical needs.”
Lore Gruenbaum, Ph.D., Chief Scientific Officer of Blood Cancer United, added, “The Beat AML Master Clinical Trial is changing the approach to treating acute myeloid leukemia with a precision medicine model. Our partnership with AVEO marks an important stage in transforming patient care and providing new therapeutic options for adults with AML.”
This study reflects the ongoing commitment of both AVEO and Blood Cancer United to collaborative research, using advanced clinical trial designs to bring new and effective therapies to patients with challenging and life-threatening blood cancers.
Health Technology Insights: Ferronova Raises $6 Million to Boost Image-Guided Cancer Surgery
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
